The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Authors: Vaz Batista, Marta ^{1, 2, 17}, Pérez-García, José Manuel ^{2, 3, 17}, Garrigós, Laia ^{3, 4}, García-Sáenz, José Ángel ⁵, Cortez, Patricia ⁶, Racca, Fabricio ⁷, Blanch, Salvador ^{2, 8}, Ruiz-Borrego, Manuel ⁹, Fernández-Ortega, Adela ¹⁰, Fernández-Abad, María ^{11, 12}, Iranzo, Vega ¹³, Gion, María ¹¹, Martrat, Griselda ², Alcalá-López, Daniel ², Pérez-Escuredo, Jhudit ², Sampayo-Cordero, Miguel ², Llombart-Cussac, Antonio ^{2, 14, 15, ∗}, Braga, Sofia ¹, Cortés, Javier ^{2, 3, 16, 18, ∗∗}

Source: In Med 10 January 2025 6(1)

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study

Authors: Calles, Antonio ^{a, ∗}, Navarro, Alejandro ^{b, c}, Doger de Speville Uribe, Bernard Gaston ^d, Colomé, Enric Álvarez ^b, de Miguel, María ^e, Álvarez, Rosa ^a, Arregui, Marta ^a, Moreno, Víctor ^d, Rocha, Pedro ^b, Calvo, Emiliano ^e, Ramon-Patino, Jorge ^e, Corral de la Fuente, Elena ^e, Alcalá-López, Daniel ^c, Boix, Olga ^c, Fernández-Pinto, Melissa ^c, Rodríguez-Morató, Jose ^c, Palmero, Ramón ^f, Nadal, Ernest ^f, Jove, Maria ^f, Felip, Enriqueta ^b

Source: In Journal of Thoracic Oncology February 2025

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Authors: García Del Muro, Xavier ^{a, ⁎}, Páez López-Bravo, David ^b, Cuéllar-Rivas, Miler Andrés ^a, Maroto, Pablo ^b, Giannatempo, Patrizia ^c, Castellano, Daniel ^d, Climent, Miguel A. ^e, P. Valderrama, Begoña ^f, Gómez de Liaño, Alfonso ^g, López-Montero, Laura ^h, Mina, Leonardo ^h, Alcalá-López, Daniel ^h, Sampayo-Cordero, Miguel ^h, Necchi, Andrea ^{i, j}

Source: In European Urology Oncology April 2025 8(2):278-286

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Authors: Llombart-Cussac, Antonio, Pérez-Garcia, José Manuel, Ruiz Borrego, Manuel, Tolosa, Pablo, Blanch, Salvador, Fernández-Ortega, Adela, Urruticoechea, Ander, Blancas, Isabel, Saura, Cristina, Rojas, Beatriz, Bermejo, Begoña, Ponce Lorenzo, José, Gion, María, Cortez-Castedo, Patricia, Llabres, Elisenda, Galve, Elena, Cueva, Juan Fernando, López, Ana, Alonso-Romero, José Luis, González-Santiago, Santiago, Martínez de Dueñas, Eduardo, Ciruelos, Eva, Martrat, Griselda, Gener, Petra, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Gómez-Peralta, Fernando, Cortés, Javier

Source: In eClinicalMedicine May 2024 71

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Authors: Pérez-García, José Manuel ^*, Cortés, Javier ^*, Ruiz-Borrego, Manuel, Colleoni, Marco, Stradella, Agostina, Bermejo, Begoña, Dalenc, Florence, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Marmé, Frederik, Cortés, Alfonso, Albacar, Cinta, Gebhart, Geraldine, Prat, Aleix, Kerrou, Khaldoun, Schmid, Peter, Braga, Sofia, Di Cosimo, Serena, Gion, Maria, Antonarelli, Gabriele, Popa, Crina, Szostak, Emilia, Alcalá-López, Daniel, Gener, Petra, Rodríguez-Morató, Jose, Mina, Leonardo, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio ^*

Source: In The Lancet 27 April-3 May 2024 403(10437):1649-1659

Building blocks of social cognition: Mirror, mentalize, share?

Authors: Alcalá-López, Daniel, Vogeley, Kai, Binkofski, Ferdinand, Bzdok, Danilo

Source: In Cortex September 2019 118:4-18

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study

Authors: Cortés, Alfonso, López-Miranda, Elena, Fernández-Ortega, Adela, Carañana, Vicente, Servitja, Sonia, Urruticoechea, Ander, Lema-Roso, Laura, Márquez, Antonia, Lazaris, Alexandros, Alcalá-López, Daniel, Mina, Leonardo, Gener, Petra, Rodríguez-Morató, Jose, Antonarelli, Gabriele, Llombart-Cussac, Antonio, Pérez-García, José, Cortés, Javier

Source: In The Breast December 2024 78

This result is not displayed to guests.
Login for full access.

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and deintensification strategies in breast cancer.

Authors: Sampayo-Cordero, Miguel, Miguel-Huguet, Bernat, Malfettone, Andrea, López-Miranda, Elena, Gion, María, Abad, Elena, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Pérez-García, José Manuel, Llombart-Cussac, Antonio, Cortés, Javier

Source: Frontiers in Oncology; 2023, p1-6, 6p

Subject Terms: OVERTREATMENT of cancer, PROOF of concept, EXPERIMENTAL design, BREAST cancer, MAXIMUM likelihood statistics, DISTRIBUTION (Probability theory)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.

Authors: López González, Ana, Del Barco Berrón, Sonia, Grau, Isabel, Galan, Maria, Castelo Fernández, Beatriz, Cortés, Alfonso, Sánchez Rovira, Pedro, Martinez-Bueno, Alejandro, Gonzalez, Xavier, García, Almudena, Gener, Petra, Mina, Leonardo, Alcalá-López, Daniel, Sampayo, Miguel, Cortés, Javier, Pérez-Garcia, José Manuel, Llombart-Cussac, Antonio, López-Miranda, Elena

Source: Cancers; Dec2022, Vol. 14 Issue 23, p5880, 12p

Subject Terms: DRUG efficacy, CONFIDENCE intervals, ONCOGENES, ANTINEOPLASTIC agents, IMMUNOMODULATORS, RANDOMIZED controlled trials, TREATMENT effectiveness, ERIBULIN, AROMATASE inhibitors, SENSITIVITY & specificity (Statistics), BREAST tumors, DRUG resistance in cancer cells, PHARMACODYNAMICS

This result is not displayed to guests.
Login for full access.

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Authors: García Del Muro, Xavier, Páez López-Bravo, David, Cuéllar-Rivas, Miler Andrés, Maroto, Pablo, Giannatempo, Patrizia, Castellano, Daniel, Climent, Miguel A., P. Valderrama, Begoña, Gómez de Liaño, Alfonso, López-Montero, Laura, Mina, Leonardo, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Necchi, Andrea

Source: European Urology Oncology; 20240101, Issue: Preprints

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).

Authors: Cortes, Javier, Pérez-García, José Manuel, Ruiz-Borrego, Manuel, Stradella, Agostina, Bermejo, Begona, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Cortés Salgado, Alfonso, Albacar, Cinta, Colleoni, Marco, Gebhart, Geraldine, Prat, Aleix, Khaldoun, Kerrou, Schmid, Peter, Di Cosimo, Serena, Popa, Crina, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio

Source: Journal of Clinical Oncology; 6/10/2023 Supplement17, Vol. 41, pLBA506-LBA506, 1p

Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.

Authors: Garcia del Muro, Xavier, Cuellar, M. Andres, Maroto-Rey, Pablo, Giannatempo, Patrizia, Castellano, Daniel, Necchi, Andrea, Climent, Miguel Ángel, Valderrama, Begoña Pérez, Gomez De Liano Lista, Alfonso, Molina, David, Mina, Leonardo, Alcalá-López, Daniel, Sampayo, Miguel, Paez, David

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5043-5043, 1p

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Authors: Llombart-Cussac, Antonio, Harper-Wynne, Catherine, Perello, Antonia, Hennequin, Audrey, Fernandez, Adela, Colleoni, Marco, Carañana, Vicente, Quiroga, Vanesa, Medioni, Jacques, Iranzo, Vega, Wheatley, Duncan, Del Barco, Sonia, Anton, Antonio, Dobi, Erion, Ruiz-Borrego, Manuel, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Sampayo-Cordero, Miguel, Pérez-García, José Manuel, Cortes, Javier

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p1001-1001, 1p